Literature DB >> 8891128

Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

K Tateda1, Y Ishii, T Matsumoto, N Furuya, M Nagashima, T Matsunaga, A Ohno, S Miyazaki, K Yamaguchi.   

Abstract

Several previous investigators have reported that long-term administration of certain macrolides is efficacious in patients with persistent pulmonary Pseudomonas aeruginosa infections, even though the clinically achievable concentrations of these medications are far below their MICs. In the present study, we examined how sub-MICs of macrolide antibiotics affect the viability of and protein synthesis in several strains of P. aeruginosa. We report that 48 h, but not 12 or 24 h, of growth on agar containing a clinically achievable concentration of azithromycin (0.5 microgram/ml, 1/128 the MIC) significantly reduces the viability of strain PAO-1. Similar effects were seen with erythromycin and clarithromycin at 2 micrograms/ml (1/128 and 1/64 the respective MICs), whereas josamycin, oleandomycin, ceftazidime, tobramycin, minocycline, and ofloxacin had no effect on viability, even following 48 h of incubation with concentrations representing relatively high fractions of their MICs. The bactericidal activity of azithromycin seen following 48 h of incubation was not limited to strain PAO-1 but was also seen against 13 of 14 clinical isolates, including both mucoid and nonmucoid strains. Although viability was not decreased prior to 48 h, we found that 4 micrograms of azithromycin per ml inhibits protein synthesis after as little as 12 h and that protein synthesis continues to decrease in a time-dependent manner. We likewise found that P. aeruginosa accumulates azithromycin intracellulary over the period from 12 to 36 h. These results suggested that sub-MICs of certain macrolides are bactericidal to P. aeruginosa when the bacteria are exposed to these antibiotics for longer periods. Exposure-dependent intracellular accumulation of the antibiotic and inhibition of protein synthesis may partially account for the antipseudomonal activity of macrolides over relatively prolonged incubation periods.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891128      PMCID: PMC163517     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

Review 2.  Molecular basis of bacterial outer membrane permeability.

Authors:  H Nikaido; M Vaara
Journal:  Microbiol Rev       Date:  1985-03

3.  Enhancement of human polymorphonuclear leucocyte motility by erythromycin in vitro and in vivo.

Authors:  A C Fernandes; R Anderson; A J Theron; G Jooné; C E Van Rensburg
Journal:  S Afr Med J       Date:  1984-08-04

4.  Diffuse panbronchiolitis. A disease of the transitional zone of the lung.

Authors:  H Homma; A Yamanaka; S Tanimoto; M Tamura; Y Chijimatsu; S Kira; T Izumi
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

5.  Evaluation of the immunostimulating activity of erythromycin in man.

Authors:  F Fraschini; F Scaglione; F Ferrara; O Marelli; P C Braga; F Teodori
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

6.  Murein and lipopolysaccharide biosynthesis in synchronized cells of Escherichia coli K 12 and the effect of penicillin G, mecillinam and nalidixic acid.

Authors:  P Essig; H H Martin; J Gmeiner
Journal:  Arch Microbiol       Date:  1982-09       Impact factor: 2.552

7.  The role of Pseudomonas aeruginosa in infections.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity.

Authors:  K Tateda; Y Ishii; Y Hirakata; T Matsumoto; A Ohno; K Yamaguchi
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

9.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis.

Authors:  J Lam; R Chan; K Lam; J W Costerton
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.

Authors:  R Mizukane; Y Hirakata; M Kaku; Y Ishii; N Furuya; K Ishida; H Koga; S Kohno; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.938

View more
  24 in total

1.  Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.

Authors:  K Tateda; R Comte; J C Pechere; T Köhler; K Yamaguchi; C Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 3.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

4.  Effect of Sub-MICs of Macrolides on the Sensitivity of Pseudomonas aeruginosa to Nitrosative Stress: Effectiveness against P. aeruginosa with and without Multidrug Resistance.

Authors:  Takeshi Shimizu; Tohru Miyoshi-Akiyama; Kohei Ogura; Shota Murata; Shota Ishige; Kiyohiro Kai; Konosuke Mitsutsuka; Haruyoshi Tomita; Koichi Tanimoto; Akio Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Macrolide immunomodulation of chronic respiratory diseases.

Authors:  Daniel P Healy
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

7.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

8.  Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis.

Authors:  K Kawamura-Sato; Y Iinuma; T Hasegawa; T Horii; T Yamashino; M Ohta
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

9.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

Review 10.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.